Cardiff Oncology Inc 's ability to collect its outstanding accounts receivable from its corporate clients, has improved in the second quarter 2026 to a ratio of 2.49, above the company average. This is a clear sign of healthy business climate in the Biotechnology & Pharmaceuticals industry and improving liquidity at their respective customers, during the second quarter 2026. Average receivable collection period, for the Cardiff Oncology Inc in Jun 30 2026 quarter, has decreased to 147 days, compared to 201 days, in the Mar 31 2026 quarter.

If we take a look into Healthcare sector 550 other companies have achieved higher receivables turnover ratio. While total ranking has deteriorated relative to the period ending Jun 30 2026 from 2833 to 3791.

What is Receivable Turnover Ratio?
What is Cardiff Oncology Inc Selling?

What is Receivable Turnover Ratio?

Select the Comparisons :

None ▼

Select the Ratio:

Accounts Receivables Turnover▼

None ▼

Accounts Receivables Turnover▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

CRDF Receivables Turnover Ratio	(Jun 30 2026) II. Quarter	(Mar 31 2026) I. Quarter	(Dec 31 2025) IV. Quarter	(Sep 30 2025) III. Quarter	(Jun 30 2025) II. Quarter
Y / Y Receivable Change	-64.07 %	-52.84 %	-76.46 %	-58.9 %	16.63 %
Y / Y Revenue Change	-14.05 %	-62.39 %	62 %	-27.27 %	-25.77 %
Receivable Turnover Ratio (TTM)	2.49	1.82	1.74	1.02	0.94
CRDF's Total Ranking	# 3791	# 2833	# 3490	# 0	# 0
Accounts Receivable average collection period days	147	200	210	357	389
Seq. Receivable Change	-1.05 %	4.95 %	-28.35 %	-51.71 %	29.88 %
Seq. Revenue Change	153.66 %	-83.13 %	102.5 %	-0.83 %	11.01 %

Receivable Turnover Company Ranking
Within:	No.
Biotechnology & Pharmaceuticals Industry	# 69
Healthcare Sector	# 551
Overall Market	# 3791

Receivable Turnover Ratio Statistics
High	Average	Low
0.06	0.02	0
(Dec 31 2012)		(Sep 30 2021)

CRDF Company Profile • Back to CRDF Efficiency Comparisons • Compare CRDF Receivables Turnover Ratio to its Competitors

Financial Statements
Cardiff Oncology Inc 's Accounts Receivable	$ 0 Millions	Visit CRDF's Balance sheet
Cardiff Oncology Inc 's Sales TTM	$ 1 Millions	Visit CRDF's Income Statement
Sources of CRDF's Revenues		Visit CRDF's Sales by Geography

Other Accounts Receivable Turnover Ratios
Biotechnology & Pharmaceuticals Industry Accounts Receivable Turnover Trends and Statistics
Healthcare Sector Accounts Receivable Turnover Statistics
Accounts Receivables Turnover Trends for overall market
CRDF's Receivable Turnover Ratio versus Biotechnology & Pharmaceuticals Industry, Healthcare Sector and total Market
Highest Ranking Accounts Receivables Turnover
Lowest Ranking Accounts Receivables Turnover

You may also want to know
CRDF's Growth Rates	CRDF's Roa	CRDF's Inventory Turnover Ratio	CRDF's Dividend Comparisons
CRDF's Profitability Ratios	CRDF's Roi	CRDF's Asset Turnover Ratio	CRDF's Dividend Growth
CRDF's Valuation Ratios	CRDF's Roe	CRDF's Financial Strength Ratios	CRDF's Dividend Payout Ratio

Companies with similar Receivables Turnover Ratio for the quarter ending Jun 30 2026, within Healthcare Sector	Receivable Turnover Ratio	Revenues for 12 Months ending Jun 30 2026	Receivable at quarter ending Jun 30 2026
Maravai Lifesciences Holdings Inc	7.39	$ 207.886 Millions	$ 28.147 Millions
Lucid Diagnostics Inc	7.33	$ 5.445 Millions	$ 0.742 Millions
Foxo Technologies Inc	7.27	$ 24.846 Millions	$ 3.420 Millions
Safe Pro Group Inc	7.23	$ 2.881 Millions	$ 0.399 Millions
Rhythm Pharmaceuticals Inc	7.18	$ 239.918 Millions	$ 33.429 Millions
Travere Therapeutics Inc	7.10	$ 591.330 Millions	$ 83.339 Millions
Angiodynamics Inc	7.08	$ 317.726 Millions	$ 44.853 Millions
Pulmonx Corporation	7.07	$ 87.393 Millions	$ 12.356 Millions
Sutro Biopharma Inc	6.98	$ 45.702 Millions	$ 6.545 Millions
Edwards Lifesciences Corporation	6.98	$ 6,512.500 Millions	$ 933.400 Millions
Beyond Air Inc	6.98	$ 6.677 Millions	$ 0.957 Millions
Quidelortho Corp	6.92	$ 2,674.200 Millions	$ 386.400 Millions
Myriad Genetics Inc	6.91	$ 805.900 Millions	$ 116.650 Millions
Ceribell Inc	6.90	$ 101.804 Millions	$ 14.749 Millions
Stryker Corp	6.89	$ 25,837.000 Millions	$ 3,749.000 Millions
Nephros Inc	6.83	$ 21.686 Millions	$ 3.173 Millions
Medpace Holdings Inc	6.82	$ 2,782.288 Millions	$ 408.189 Millions
Opko Health Inc	6.79	$ 587.896 Millions	$ 86.589 Millions
Atara Biotherapeutics Inc	6.79	$ 6.452 Millions	$ 0.950 Millions
Rapid Micro Biosystems Inc	6.76	$ 34.545 Millions	$ 5.111 Millions
Universal Health Services Inc	6.75	$ 18,114.487 Millions	$ 2,683.492 Millions
3m Company	6.72	$ 25,180.000 Millions	$ 3,747.750 Millions
Phibro Animal Health Corporation	6.70	$ 1,516.861 Millions	$ 226.555 Millions
Eton Pharmaceuticals Inc	6.67	$ 105.279 Millions	$ 15.783 Millions
Neuropace Inc	6.65	$ 98.620 Millions	$ 14.834 Millions
Aspira Women s Health inc	6.65	$ 9.029 Millions	$ 1.358 Millions
Bionano Genomics Inc	6.62	$ 30.176 Millions	$ 4.556 Millions
Liquidia Corporation	6.61	$ 450.907 Millions	$ 68.198 Millions
Pmgc Holdings Inc	6.57	$ 2.579 Millions	$ 0.393 Millions
Embecta Corp	6.50	$ 1,019.700 Millions	$ 156.775 Millions

Date modified: 2026-09-03T11:39:45+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.